Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Micro ARN como marcadores para el diagnóstico del daño alveolar difuso y predicción de resultados del síndrome de dificultad respiratoria aguda en suero de pacientes en cuidados intensivos

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20140127002
Publicado:
06/02/2015
Caducidad:
12/08/2015
Resumen:
Un consorcio español formado por hospitales y centros de investigación ha descubierto un conjunto de micro ARN (miARN) para diagnosticar el estado histológico del daño alveolar difuso (DAD) y predecir los resultados del síndrome de dificultad respiratoria aguda en muestras de suero de pacientes en cuidados intensivos. También es posible confirmar el estado de otras patologías con riesgo de desarrollar daño alveolar difuso. Esta invención permite desarrollar nuevos tratamientos para estas patologías. Se buscan empresas interesadas en desarrollar conjuntamente el diagnóstico y tratamiento y en establecer acuerdos de licencia.

Details

Tittle:
Set of micro RNAs as Markers for the diagnosis of Diffuse Alveolar Damage and outcome prediction of Acute Respiratory Distress Syndrome in serum of critical care patients.
Summary:
A Spanish Consortium of Hospitals and Research Centers have discovered a set of micro RNAS (miRNAs) that diagnoses the histological condition of diffuse alveolar damage (DAD) and predict the outcome of acute respiratory distress syndrome in serum samples. The set can also confirm the state of other pathologies in risk of developing DAD. New treatments for such pathologies could develop from the invention. Companies interested in codevelopment of diagnosis/treatment and/or in licensing are sought
Description:
Acute Respiratory Distress Syndrome (ARDS) is a very serious pathology, frequent in intensive care units and associated with a mortality rate of 40%. The pathology is diagnosed by clinical symptoms; however the presence of diffuse alveolar damage (DAD) is the gold standard method to confirm the histopathological condition of ARDS since other diseases can present similar symptoms such as pulmonary embolism or pneumonia. Moreover, several studies reveal that after biopsy around half of the cases with a clinical diagnose of ARDS do not present DAD. DAD could represent a specific clinical phenotype, and the only way to ensure the presence of DAD is by pulmonary biopsy, a very invasive technique that entails high risks, especially for intensive care patients.

Furthermore, DAD can also occur during development of other diseases and health conditions such as: sepsis, serious infections, traumas, pancreatitis, bacterial an viral pneumonias, multiple blood transfusion, post-operatory of high risk surgery...

Since the intensive care units are where all these pathologies with such high mortality rates occur, there is a clear need to have early and specific tests that can help distinguishing the different origins and states of these conditions in order to target them with specific and effective treatments as soon as possible.

Furthermore there is an economic interest since the current absence of an specific test to identify different populations of patients with the same clinical condition makes the design of specific effective innovative therapeutic strategies a difficult task, and hinders the application of efficient treatments to the right patient population without wasting resources.

The present invention refers to a set of miRNAs which expression identifies, in serum sample of patients, the presence of DAD with a specificity higher than 75%. The method therefore could be a diagnosis tool for DAD for all the health conditions with a high risk to develop it and a confirmation tool for those patients with clinical suspicion of ARDS.

The invention translates into clinical and economic advantages, which are summarized in the previous paragraph, for the diagnosis in hospitals. Moreover the association of those miRNAs with DAD opens the possibility of using them as therapeutic targets for the improvement of pulmonary function in such pathologies since they are known regulators and their expression could be modified.

The Spanish research group implicated in the invention consists of Biologists and Critical Care Doctors and is devoted to critical care and respiratory medicine for more than 30 years. The group works in a public hospital, has been involved in several national and international studies in the field of acute lung injury, sepsis, and mechanical ventilation and coordinates a Spanish program in acute lung injury for a Spanish respiratory diseases consortium that brings together more than 30 groups from research institutions as well as hospitals. Furthermore, the group has a broad expertise in cell and animal models for these diseases as well as access to clinical and biological material for the studies.

They are looking for biotech or biopharmaceutical Companies interested in collaborating in the development of diagnosis and/or treatment based on this invention and/or in licensing.
Advantages and Innovations:
Acute Respiratory Distress Syndrome (ARDS) has a high incidence in intensive Care Units and is associated with high mortality. There is a need for non-invasive, early, specific diagnostic tests in order to initiate quick specific effective treatments in the population of patients that could benefit from them. The presence of diffuse alveolar damage (DAD) is the gold standard method for confirming the histopathological condition of ARDS. However, several studies reveal that around half of the cases with clinical diagnose of ARDS did not present DAD after autopsy. DAD could define a specific clinical phenotype, and the only way to ensure the presence of DAD is by pulmonary biopsy, which entails a high risk, especially for critical patients, so the diagnosis is mainly made post-mortem.

The main advantages of these markers for the diagnosis of DAD and prediction of ARDS prognosis are:

1. It is a minimally invasive method, and there is no current method in the market that can ensure the presence of this histological condition other than pulmonary biopsy.
2. Can help to clinically predict the outcome of ARDS in an early and specific way.
3. It could also detect DAD in other pathologies different from ARDS that have a high risk of developing it such us: sepsis, serious infections, traumas, pancreatitis, bacterial and viral pneumonias, multiple blood transfusion, post-operatory of high-risk surgery...
4. Can be used to dissect a homogeneous population of ARDS patients with DAD in order to test innovative treatments.
5. Can help to stratify the risk of adverse outcome in ARDS patients.
6. The correct identification of a health condition and the origin of a disease can help using the most efficient treatment for the appropriate patient population without wasting economical resources.

Furthermore these miRNAs could be of use as therapeutic targets in the development of new specific treatments for ARDS and pulmonary function by exploiting their interference me
Stage of Development:
Field tested/evaluated
IPs:
Secret Know-how
CommeR Statunts Regarding IPR Status:
A patent is being written

Partner sought

Type and Role of Partner Sought:
Diagnostic and/or Biotech or Biopharmaceutical companies for co-development and commercialization of the product.

Specific roles should be the development of a clinical diagnostic kit, which could be as a part of a point of care, commercialization, collaboration in studies for broader applications of the technology in different patient populations and co-development of possible treatments of the pathology based in the technology findings.

The specific area of activity of the partner could be: critical care, acute diseases, and respiratory diseases.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French
Spanish

Keywords

Technology Keywords:
06001005 Diagnósticos, diagnosis
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos